Reumatoscience

Subscreva-se para receber todo mês uma superdose de conhecimento!

Baker et al. validate RALI (RA Low Inflammatory Activity) using modified scores that drop patient global & tender joints.
Cutoffs: M-DAS28 <1.4, M-SDAI ≤3, M-CDAI ≤2.
RALI > remission (VARA: 44% vs 32%), similar imaging outcomes, and lower CV risk & mortality. #ACR26

Immune checkpoint inhibitor-associated arthritis: 50% persistence after ICI stopped Kate Harnden et al. #ACR26

24w of the Be-BOLD study presented by prof. Joseph Merola #ACR26

Starting day 3! #ACR26 Lifestyle intervention in RÃ

In APs patients: 42% sacroiliac joint inflammation (at least unilateral) 35% bilateral sacroiliitis Screening for every APs patients Prof. Dafna Gladman, #ACR26

The genetic conection between APs and AS: HLA-B27 #ACR26

Ankylosing spondylitis and psoriatic arthritis differences Prof. Dafna Gladman #ACR26

GLP-1 RAs in RA: lower malignancy risk overall, including 38% less lung cancer and 52% less non-Hodgkin lymphoma. Dawit Yesho et al. #ACR26

2026 ACR/SAA/SPARTAN Guidelines for the Treatment of Axial Spondyloarthritis, Liron Caplan. #ACR26 Against treat-to-target strategy!

Focus score predicts lymphoma. Professor Benjamin Fisher, Birmingham, UK #ACR26

Sjogren’s Disease. Great talk from prof Ghaith Noaiseh, MD, University of Kansas Medical Center #ACR26

Let’s begin Day 2! #ACR26

End of the day 1? Not yet! @ACRheum #ACR26

Prof. Karen H. Costenbader: “No data on transdermal HT in aPL+ or in SARDs, but for severe symptoms, low-dose transdermal HT presumed lower thrombotic risk” #ACR26 @ACRheum

When HT is not an option in rheumatic disease… Prof. Karen H. Costenbader #ACR2026 @ACRheum

Hormonal therapy - who is the best candidate? Excellent talk - Prof Stephanie Faubion #ACR26 @ACRheum

Abs 0449: JAKi in RA-ILD (n=31, 5 Japanese centers): DAS28 3.9→1.6 at 12 mo; HRCT stable in 20/31, improved in 9/31; PFTs unchanged. Lung US Pleural Scale fell in a small subgroup. Congrats to @lunalbum6 and team. #ACR26